Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Southern California
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Federation Francophone de Cancerologie Digestive
Bayer
Georgetown University
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Basilea Pharmaceutica
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
Beth Israel Deaconess Medical Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Northwestern University
M.D. Anderson Cancer Center
Imunon
BTG International Inc.
National Institutes of Health Clinical Center (CC)
Yale University
New Mexico Cancer Research Alliance
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
SillaJen, Inc.
Jonsson Comprehensive Cancer Center
Massachusetts General Hospital
Yale University
Brown University
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Emory University
Medical University of South Carolina
Yale University
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Roswell Park Cancer Institute
Roswell Park Cancer Institute
City of Hope Medical Center
University of Michigan Rogel Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University of Miami
National Institutes of Health Clinical Center (CC)
Stanford University
Emory University
SillaJen, Inc.
Novartis
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
University of Utah